HER2+ breast cancer
Oncology · 2006–2025
31decisions
11medicines
13carried consumer input
66individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| pertuzumab Neoadjuvant treatment of patients with HER2-positive, locally advanced, inflammatory or early stage (>2 cm in diameter or node positive) early breast cancer… | Mar 2025 | Recommended with restriction | input received Breast Cancer Network Australia · Rare Cancers Australia · Medical Oncology Group |
| tucatinib Metastatic (Stage IV) HER2-positive breast cancer in patients who have received at least two prior lines of HER2-directed therapy or who have progressed on… | Nov 2025 | Recommended with restriction | 5 individuals |
| trastuzumab deruxtecan Treatment of human epidermal growth factor receptor 2 (HER2) positive metastatic breast cancer (mBC) for patients who have progressed following a prior HER2… | Jul 2022 | Not recommended | 4 individuals Breast Cancer Network Australia · Medical Oncology Group |
| tucatinib HER2-positive metastatic breast cancer, including patients with brain metastases, in previously treated patients who have progressed following at least two… | Mar 2021 | Not recommended | 2 individuals Cancer Network Australia · Medical Oncology Group |
| trastuzumab Treatment of HER2-positive breast cancer (early, locally advanced, and metastatic Stage IV) and metastatic Stage IV HER2-positive adenocarcinoma of the stomach… | Nov 2021 | Recommended | none received |
| pertuzumab Neoadjuvant treatment in patients with HER2-positive locally advanced, inflammatory or early stage (≥2 cm in diameter or node positive) breast cancer, in… | Mar 2020 | Not recommended | input received Breast Cancer Network Australia |
| trastuzumab HER2-positive early, locally advanced and metastatic breast cancer, and HER2-positive metastatic gastric cancer. | Jul 2019 | Recommended | none received |
| trastuzumab HER2-positive early, locally advanced and metastatic breast cancer, and HER2-positive metastatic gastric cancer. | Jul 2019 | Recommended with restriction | none received |
| neratinib Extended adjuvant treatment of adult patients with HER2-positive, hormone receptor positive, early-stage breast cancer who have completed prior adjuvant… | Mar 2019 | Not recommended | 3 individuals Breast Cancer Network Australia · Medical Oncology Group |
| pertuzumab Adjuvant treatment of HER2-positive, lymph node-positive early breast cancer in combination with trastuzumab and chemotherapy. | Mar 2019 | Not recommended | 1 individuals Breast Cancer Network Australia · Medical Oncology Group |
| trastuzumab HER2-positive early, locally advanced and metastatic breast cancer, and HER2-positive metastatic gastric cancer. | Mar 2019 | Recommended | none received |
| trastuzumab HER2-positive early, locally advanced and metastatic breast cancer, and HER2-positive metastatic gastric cancer. | Mar 2019 | Recommended | none received |
| neratinib Extended adjuvant treatment of adult patients with HER2-positive, hormone receptor-positive, early breast cancer who have completed prior adjuvant… | Nov 2019 | Not recommended | 37 individuals Breast Cancer Network Australia · Medical Oncology Group |
| trastuzumab emtansine Adjuvant therapy of patients with HER2-positive early breast cancer with residual disease following HER2-targeted neoadjuvant therapy that included trastuzumab… | Nov 2019 | Recommended with restriction | input received Breast Cancer Network Australia · Medical Oncology Group |
| trastuzumab HER2-positive early, locally advanced and metastatic breast cancer, and HER2-positive metastatic gastric cancer. Biosimilar to Herceptin. | Nov 2019 | Recommended | none received |
| pertuzumab HER2 positive, lymph node positive, early breast cancer in the adjuvant setting (in combination with trastuzumab and chemotherapy) | Jul 2018 | Not recommended | 1 individuals Medical Oncology Group |
| trastuzumab HER2-positive early breast cancer, locally advanced HER2-positive breast cancer, and metastatic (Stage IV) HER2-positive breast cancer. | Jul 2015 | Recommended | input received |
| nab-paclitaxel Treatment of HER2 positive metastatic breast cancer in combination with trastuzumab. | Nov 2015 | Not recommended | input received Medical Oncology Group · Breast Cancer Network Australia |
| pertuzumab Treatment of HER2-positive metastatic breast cancer in combination with trastuzumab and docetaxel for patients who have not received prior anti-HER2 therapy or… | Mar 2014 | Deferred | unclear |
| trastuzumab emtansine HER2-positive metastatic breast cancer (stage IV) in patients who have received prior therapy with trastuzumab and a taxane, with disease progression despite… | Mar 2014 | Deferred | unclear |
| trastuzumab; pertuzumab; trastuzumab emtansine Treatment of HER2-positive metastatic breast cancer. Trastuzumab for first-line and second-/later-line treatment; pertuzumab in combination with trastuzumab… | Nov 2014 | Recommended; Deferred; Recommended | 13 individuals |
| trastuzumab emtansine Treatment of patients with HER2-positive unresectable locally advanced or metastatic breast cancer (stage IV) who have received prior therapy with trastuzumab… | Jul 2013 | Recommended with restriction | unclear |
| trastuzumab Initial and continuing treatment of HER2-positive locally advanced breast cancer commencing concurrently with neoadjuvant chemotherapy. | Jul 2012 | Recommended with restriction | no section in document |
| pegfilgrastim Primary prophylaxis for chemotherapy-induced neutropenia in patients with breast cancer treated with docetaxel. | Mar 2008 | Not recommended | no section in document |
| trastuzumab Treatment of patients with human epidermal growth factor receptor 2 (HER-2) positive metastatic breast cancer, either in combination with taxanes for patients… | Nov 2008 | Noted | no section in document |
| lapatinib ditosylate monohydrate Treatment of patients with advanced or metastatic HER2-positive breast cancer in combination with capecitabine, in patients whose tumours have progressed after… | Jul 2007 | Not recommended | no section in document |
| lapatinib ditosylate monohydrate Treatment of patients with advanced or metastatic breast cancer whose tumours overexpress HER2 (ErbB2) and who have received prior therapy including… | Jul 2007 | Not recommended | no section in document |
| lapatinib ditosylate Metastatic HER2-positive breast cancer in patients who have received prior therapy with anthracycline and taxane, and whose disease progresses despite… | Nov 2007 | Not recommended | no section in document |
| lapatinib ditosylate Treatment of metastatic HER2-positive breast cancer in patients who have received prior therapy with an anthracycline and a taxane, and whose disease has… | Nov 2007 | Not recommended | no section in document |
| trastuzumab Treatment of patients with HER2 positive early breast cancer following surgery in association with chemotherapy, in patients with node-positive disease or… | Jul 2006 | Recommended with restriction | no section in document |
| trastuzumab Treatment of patients with HER2 positive early breast cancer following surgery in association with chemotherapy, commencing concurrently with adjuvant… | Jul 2006 | Recommended with restriction | no section in document |
Who spoke
Medical Oncology Group · Breast Cancer Network Australia · Rare Cancers Australia · Cancer Network Australia
What the PBS pays
$467M in government benefit over 2024–25, across 271,775 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| trastuzumab; pertuzumab; trastuzumab emtansine | $181.8M |
| trastuzumab deruxtecan | $98.9M |
| pertuzumab | $83.6M |
| trastuzumab | $54.3M |
| trastuzumab emtansine | $43.9M |
| pegfilgrastim | $4.3M |
Appraised elsewhere
NICE, in England and Wales, has appraised 11 technologies for this condition, recommending 10 and declining 1. A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
| Technology | Appraisal | Outcome | Date |
|---|---|---|---|
| trastuzumab deruxtecanTrastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 1 or more anti-HER2 treatments | TA862 | recommended restricted | 2023-02 |
| tucatinibTucatinib with trastuzumab and capecitabine for treating HER2-positive advanced breast cancer after 2 or more anti-HER2 therapies | TA786 | recommended restricted | 2022-04 |
| trastuzumab deruxtecanTrastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies | TA704 | recommended restricted | 2021-05 |
| trastuzumab emtansineTrastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer | TA632 | recommended restricted | 2020-06 |
| neratinibNeratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab | TA612 | recommended restricted | 2019-11 |
| pertuzumabPertuzumab for adjuvant treatment of HER2-positive early stage breast cancer | TA569 | recommended restricted | 2019-03 |
| pertuzumabPertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer | TA509 | recommended restricted | 2018-03 |
| trastuzumab emtansineTrastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane | TA458 | recommended restricted | 2017-07 |
| pertuzumabPertuzumab for the neoadjuvant treatment of HER2-positive breast cancer | TA424 | recommended restricted | 2016-12 |
| lapatinib or trastuzumabLapatinib or trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer that overexpresses HER2 | TA257 | not recommended | 2012-06 |
| guidance on the use of trastuzumabGuidance on the use of trastuzumab for the treatment of advanced breast cancer | TA34 | recommended | 2002-03 |
Registered, not subsidised
Medicines on the ARTG for this condition with no PBAC record at all. Registration and subsidy are separate decisions: a medicine can be legally available in Australia and never have been put to the committee.
| Medicine | On the ARTG since | Registrations |
|---|---|---|
| lapatinibTYKERB lapatinib 250mg (as ditosilate monohydrate) tablet blister pack | 2007 | 2 |
The ARTG export holds current registrations only, so the year is the earliest entry still on the register rather than a first-registration date. The condition here comes from the registered label, which is usually broader than the population a sponsor asks to have subsidised.
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 13 of 21 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.